Nevrargenics

#Amyotrophic lateral sclerosis (ALS) #Motor neurone disease #Neurodegenerative disorders #Neuroscience #Nevrargenics

Promising new therapy for ALS progresses to human trials

A new treatment for the most common type of motor neurone disease (MND) could improve the neuronal health of sufferers and allow their nervous systems to improve regeneration. Ellorarxine, a novel drug compound developed by Nevrargenics, has demonstrated antioxidant and anti-inflammatory effects, which make it a… Read More

#News

Neurons
#Aberdeen University #Durham University #Neurodegenerative disorders #Neuroscience #Nevrargenics #Preclinical investigations

Novel drug reduces neuronal death in neurodegenerative disease

New research has shown that Ellorarxine, a novel drug compound developed by biotech Nevrargenics, provides a robust neuroprotective effect and reduces neuronal death in cell models of neurodegenerative disease. The peer reviewed study published in Frontiers in Neuroscience was conducted by academics at Aberdeen and… Read More

#News